Abstract
On 10 August 2007, Justice Linda Dobbs handed down the High Court's judgment on a legal challenge to the guidance on the use of cholinesterase inhibitors for the treatment of people with Alzheimer's disease published by the National Institute for Health and Clinical Excellence (NICE). In November 2006, NICE amended its 2001 guidance and recommended that donepezil (Aricept), rivastigmine (Exelon) and galantamine (Reminyl) should no longer be available to patients in the mild stages of Alzheimer's disease. The makers of Aricept, Eisai, brought the High Court challenge and the Alzheimer's Society took part as an interested party. Four comments on the implications of the judgment follow.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
